Oxana Polyakova

GlaxoSmithKline R&D, Gunnels Wood Road
Stevenage, ENG SG12NY, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Corrigendum to 'Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors' [Bioorg. Med. Chem. Lett. 29 (2019) 126675].

Corrigendum to 'Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors' [Bioorg. Med. Chem. Lett. 29 (2019) 126675].

Journal: Bioorganic & medicinal chemistry letters

Published: December 21, 2019

Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.

Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: July 23, 2019

Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.

Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.

Journal: Bioorganic & medicinal chemistry letters

Published: February 18, 2019

Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndrome.

Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndrome.

Journal: Acta crystallographica. Section F, Structural biology communications

Published: January 14, 2019

Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.

Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.

Journal: Bioorganic & medicinal chemistry letters

Published: December 11, 2018

The γδTCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness.

The γδTCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness.

Journal: Nature immunology

Published: May 26, 2018

Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation.

Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation.

Journal: Nature chemical biology

Published: May 27, 2014

Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket.

Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket.

Journal: The Journal of biological chemistry

Published: August 13, 2013

Identification of novel interacting partners of Sirtuin6.

Identification of novel interacting partners of Sirtuin6.

Journal: PloS one

Published: August 29, 2012

Over expression of wild type or a catalytically dead mutant of Sirtuin 6 does not influence NFκB responses.

Over expression of wild type or a catalytically dead mutant of Sirtuin 6 does not influence NFκB responses.

Journal: PloS one

Published: February 24, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026